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Abstract
Introduction—This study evaluated the five-year observed survival rates of American Indians/
Alaskan Native, African American, and white cancer patients among various demographic 
characteristics in Oklahoma focusing on lung and bronchus, colon and rectum, female breast, and 
prostate for the cancer patients diagnosed between 1997 and 2008.
Methods—The five-year observed survival rates were calculated for overall cancer and specific 
cancer sites, using Kaplan-Meier method with data from the Oklahoma Central Cancer Registry.
Results—Overall, 51.5% patients diagnosed with cancer survived for five years. For specific 
sites we found: 79.2% for female breast cancer survived; 77.5% for prostate cancer; 12.9% for 
lung and bronchus cancer; and 49.9% for colorectal cancer.
Conclusions—The five-year observed survival rates in Oklahoma were consistent with national 
trends. Overall, cancer survival seems to be improving over time, but there remains disparity with 
the AA and AI/AN populations in contrast to whites in Oklahoma.
INTRODUCTION
Cancer survival is a complex combination of prevention, screening, and treatment. Increased 
survival is only positive when it is accompanied by decreased burden of disease.1 Improved 
survival can also occur as a result of increased disease burden, which may occur with 
increased screening resulting in diagnosing cancer at an earlier stage as seen with 
mammography for breast cancer. Increased survival may also be seen as a result of improved 
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treatment or improved management of co-morbid conditions such as diabetes or heart 
disease.1 Five-year survival may be seen as an important indicator of potential disparities 
within a population. Cancer is the second most common cause of death in the United States 
(US) and Oklahoma.2 In 2012, Oklahoma ranked 5th highest in cancer mortality with an 
age-adjusted rate of 193.8 per 100,000 compared to 166.8 per 100,000 in the US.3 
Oklahoma had a population of around 3.8 million in 2013, out of which, 13.2% were 
American Indian or Alaskan Native (AI/AN) race alone or in combination with one or more 
other races and 8.8% were African American (AA) race alone or in combination with one or 
more other races.4
The patterns of cancer occurrence among AI/AN populations and AA populations are 
distinctive because of the unique characteristics of history, culture, geographic location, and 
access to healthcare facilities.5-7 The AI/AN population is comprised of hundreds of tribes 
and linguistic groups, offering great diversity in culture.5 Among the major risk factors for 
cancer, the abuse of commercial tobacco and alcohol, lower physical activity levels, and high 
levels of obesity have been observed at greater rates in AA and AI/AN populations.5,8,9 The 
cancer mortality rate is also influenced by the stage at which the cancer is diagnosed in 
addition to access to healthcare. The primary healthcare in AI/AN populations is provided 
by the Indian Health Service (IHS) or other tribally operated programs.11 Specialty care 
services, including cancer treatment, are only accessible through non-Federal Purchased/
Referred Care (PRC) services with IHS.5 Health services are available only to those who are 
enrolled members of tribal nations or otherwise eligible, and therefore, treatment becomes 
very difficult and unaffordable to those who do not fulfill eligibility requirements or do not 
have access to PRC services.5 Among AAs, there are also unique histories of segregation 
and lack of access to health. Both AI/AN and AA populations generally have lower 
socioeconomic status and less access to healthcare than whites.10 Many studies have 
reviewed segregation issues, historical trauma, racism, institutional racism, intergenerational 
poverty and the lack of access to care among AA and AI/AN populations.8,11-14
Multiple studies have identified disparities in cancer survival in the US.11,15-23 A few studies 
have focused specifically on the burden of cancer incidence, mortality and survival among 
the AA and AI/AN populations.11,15-26 These studies have demonstrated that the survival of 
cancer patients in AA and AI/AN populations is lower than that of the white 
population.24,25,27 However, cancer survival among AA and AI/AN populations in 
Oklahoma has not yet been studied.
The goal of this study was to evaluate the five-year observed survival rates among AI/AN, 
AA, and white populations in Oklahoma. This study focused on overall as well as site-
specific five-year survival rates for lung and bronchus, colon and rectum, female breast, and 
prostate cancers diagnosed between 1997 and 2008. This study was approved by the 
institutional review boards at the University of Oklahoma Health Sciences Center and the 
Oklahoma State Department of Health.
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The data for this study was obtained from the Oklahoma Central Cancer Registry (OCCR) 
and included all patients diagnosed with cancer (n=220,816) between 1997 and 2008 in 
Oklahoma. Cases were excluded if they met the following exclusion criteria: benign or 
borderline behavior codes (n=1,811), death certificate only as the reporting source 
(n=5,225), autopsy only as the reporting source (n=93), zero survival time or fewer than zero 
days survival (n=3,796). With these exclusions, the total sample size was 209,891. Vital 
status on each case was ascertained through November 1, 2014. OCCR does not participate 
in active follow-up, however, the OCCR periodically conducts follow-up of those included 
in the registry, along with linkage with the Oklahoma Mortality Data, the Social Security 
Death Index, and the National Death Index (NDI) to identify those who are deceased.28 
Therefore, the presumed alive assumption for those not listed as dead was used.29
Data Source
The data used in this study were from the OCCR, a population-based public health 
surveillance database that includes information on all cases of reportable cancers diagnosed 
or treated in Oklahoma. The OCCR started collecting information on cancer cases from 
January 1, 1997. The OCCR was a gold certified registry from the North American 
Association of Central Cancer Registries (NAACCR) for the years of this study.30
Cancer stage at diagnosis was determined using the SEER Summary Stage 2000 for cases 
diagnosed in from 1997 through 2003, and using the derived SEER Summary Stage 2000 for 
cases diagnosed in 2004 through 2008. Cancer stage at diagnosis was determined using the 
standard SEER definition, in situ, localized, regional, distant, and unstaged. Participants’ 
age, race, date of diagnosis, date of last contact, cancer stage, sex, survival time, primary 
payer at diagnosis, marital status, county of residence at diagnosis, and vital status were 
either extracted from the OCCR or calculated based on the available information. An 
individual’s race was determined using the OCCR primary race variable for all racial groups 
except AI/ANs, whose race was determined using the IHS link variable in combination with 
the primary race. The rural/urban continuum 2000 was used to classify patients county of 
residence at diagnosis as either metropolitan or non-metropolitan.31
Misclassification of race had been a major issue in the past in central cancer registries 
particularly for correctly identifying the AI/AN population. Cancer registries generally 
extract race and ethnicity from medical records. Several studies reported misclassification of 
race that varied by region and resulted in significantly lowered cancer rates in AI/AN 
populations.5,32,33 To address this issue, the US cancer registry systems have been enhanced 
by record linkages to reduce racial misclassification.32 In this study, the AI/AN population 
included those reported as primary race of AI/AN in addition to those who linked with IHS 
records (regardless of primary race). The IHS linkage procedures for AI/AN population are 
explained in detail in other studies.32 AA and white population have been coded from the 
primary race variable excluding those who linked to IHS.
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Survival time was calculated by subtracting date of diagnosis from date of death for patients 
who died and dividing the outcome by 365.24 to get survival time in years. If patients 
remained alive as of last contact or November 1, 2014, their survival times were considered 
as censored. For those dates of diagnosis that were missing, standard SEER methods were 
used.34 To reduce overestimation or underestimation of survival due to missing day or month 
in the date variables, the following imputation method was implemented.34 For missing days 
the midpoint of the month was used; for those with missing months and days, January 1 for 
the given year was used. For those that lacked the day but had the year and month, the 15th 
day of the month was assigned. for those with missing months and days, January 1 for the 
given year was used. For those missing the last date of contact it was assumed they were 
alive and the November 1, 2014 date was used.
Statistical Methods
We calculated descriptive statistics using percentages of overall cancer and each cancer site 
diagnosed by sex, age group, race, ethnicity (Hispanic and non-Hispanic), year of diagnosis 
group, marital status, primary payer at diagnosis, and stages of cancer. For race-specific 
analyses, we evaluated those classified as white, AA, or AI/AN. The age variable was 
categorized into five groups: younger than 40, 40-49, 50-59, 60-69 and 70 years and older. 
The stages of cancer were grouped into five categories: in situ, localized, regional, distant, 
and unstaged. The diagnosis years were categorized into three groups: 1997-2000, 
2001-2004 and 2005-2008. Marital status was classified as single, married, separated, 
divorced, widowed and unknown for the overall analysis, but was categorized into three 
groups: married, single and unknown for race-specific analyses. Primary payer at diagnosis 
status was categorized as uninsured, insured, Medicaid, Medicare, Medicare/Medicaid, 
Veterans Affair (VA)/TRICARE/Military, IHS, and unknown. The five-year observed 
survival rates and their 95% confidence intervals (CI) were calculated for overall cancer and 
specific cancer sites, stratified by sex, age group, race, ethnicity, year of diagnosis group, 
marital status, primary payer at diagnosis, and stages of cancer using Kaplan-Meier 
method.35 Difference in survival function between groups, such as the differences between 
the three main racial groups stratified by sex, age group and stages of cancer, were assessed 
by the log-rank test (two-sided), at 0.05 alpha level of significance.35 If the overall log-rank 
test was significant, pair-wise log-rank test using the Šidák method performed with whites as 




Overall, 51.5% patients diagnosed with cancer survived for five years (all groups were 
significant at a p<0.0001 (Table 1). There was a relatively small but statistically significant 
improvement in overall five-year survival from 1997-2000, to 2001-2004 and 2005-2008 at 
48.3%, 51.6%, and 54.0% respectively. The trend for overall cancer survival was as expected 
with younger age groups having had higher survival rates in contrast to those in older age 
groups. Those aged 40 years or younger had the highest percentage of survival at 77.2% in 
contrast to those aged 70 years and older at only 38.3% with the intervening age groups 
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being between those two extremes. Women were significantly more likely to survive five 
years with 55.3% compared to men at 47.7%. Those individuals living in non-metropolitan 
counties were slightly but significantly less likely to survive five years with 48.8% compared 
to those in metropolitan counties 53.3%. Those who were married were significantly more 
likely to survive five years after diagnosis at 56.7% in contrast to those that were single at 
49.7% or whose marital status was unknown at 42.5%.
Primary payer at diagnosis was an important indicator of potential access to screening and 
early diagnosis as an approximation for socio-economic status (SES). There was a 
statistically significant difference between those insured and those with other primary payer 
sources (Table 1). Sixty nine percent (68.6%) of those insured survived five years contrasted 
with 33.0% for those on both Medicare and Medicaid, 40.0% uninsured at diagnosis, 43.6% 
with Medicaid at diagnosis, 44.1% with Medicare at diagnosis, and 49.1% with VA/
TRICARE/Military at diagnosis. Among those with IHS as the primary payer at diagnosis, 
55.7% survived at least five years, which was significantly worse than insured, but better 
than those on other public payer sources (VA/TRICARE/Military, Medicare, Medicaid and 
Medicare/Medicaid) (Table 1).
As expected, as the stage of diagnosis worsened so did the survival, with the five-year 
observed survival being: 84.8% for those diagnosed at in situ; 72.0% for those diagnosed at 
localized; 48.9% for those diagnosed at regional; 18.5% for those diagnosed at distant stage; 
and 31.1% for those unstaged at diagnosis (Table 1).
Overall, whites and AI/ANs had similar five-year survival at 51.6% and 50.9% in contrast to 
47.1% among AAs. Those identified as Hispanic had a significantly higher survival at 60.1% 
compared to non-Hispanics at 51.3% (Table 1). Consistent with overall cancer survival 
trends, similar trends were observed by race for each of the demographic characteristics 
(Table 2). However, the study also showed two vital trends. First, observed survival among 
AA was consistently worse than that in whites or AI/ANs, with the exception of those with 
primary payer of Medicaid and VA/TRICARE/Military and among those who were 
diagnosed at in situ or localized stage (Table 2). Overall observed survival was lower for AA 
in contrast to AI/AN with the exception of years 2005-2008, among those aged 40-49, 
50-59, and 60-69, among males, married and single, uninsured, Medicaid, Medicare/
Medicaid, VA/TRICARE/Military, in situ, localized and regional (Table 2). The second 
important trend was that while AI/ANs had similar overall observed survival compared to 
whites, the trends were inconsistent. The most recent years 2005-2008 were trending toward 
being worse for AI/AN populations compared to whites at 50.1% and 54.5% (p=0.07) 
respectively (Table 2). Additionally, each age group and males had lower observed survival 
compared to the same demographic groups among whites (Table 2). For primary payer, 
when compared to whites, AI/ANs had lower five-year survival among those uninsured 
(34.5% vs 40.3%, p=0.07) and those with Medicare (42.5% vs 44.4%, p<0.0001), however, 
had higher survival with unknown primary payer (55.1% vs 48.0%, p<0.0001). Moreover, 
those AI/ANs with distant stage had increased observed survival at 20.9% in contrast to 
18.3% for whites, although not significantly different (p=0.09).
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Overall, 79.2% of women diagnosed with breast cancer survived for five years (all groups 
were significant at a p<0.0001 unless stated otherwise; Table 1). There was a small but 
statistically significant improvement in overall observed survival for women diagnosed from 
1997-2000, to 2001-2004 and 2005-2008 at 76.4%, 79.9%, and 81.1% respectively. Women 
aged 70 years and older were less likely to survive five years at 66.8% compared to all other 
age groups. Women living in non-metropolitan counties at diagnosis were slightly less likely 
to survive five years at 77.2% compared to those in metropolitan counties at 80.3%. Married 
women were significantly more likely to survive five years 85.7% compared to single 
women at 77.5% or whose marital status was unknown at 67.8%.
The percentage of women surviving breast cancer for five years decreased as stage of 
diagnosis worsened: 92.9% of those diagnosed at in situ; 85.9% diagnosed at localized 
stage; 74.4% diagnosed at regional stage; 24.0% diagnosed at distant stage; and those 
unstaged at diagnosis had 54.4% five-year survival (Table 1).
There was a statistically significant difference in observed survival based on primary payer 
sources (Table 1). Women with VA/TRICARE/Military as their primary payer at diagnosis 
had the highest survival at 91.4% followed closely by women with insurance at 89.3%. 
Among those with both Medicare and Medicaid as their primary payer at diagnosis, only 
57.8% survived five years.
Whites and AI/AN women had similar five-year observed survival at 79.4% and 80.2%, in 
contrast to 73.4% of AA women who survived five years (p<0.0001). Trends in survival for 
each of these demographic characteristics of women diagnosed with female breast cancer by 
race were consistent with the overall survival within each racial group. There was one 
overarching and disconcerting trend: observed survival for AA women was consistently 
worse than white or AI/AN women, with the exception of a few very specific groups, 
including among those with Medicare and Medicaid at diagnosis and those diagnosed at the 
in situ stage. While there was no significant differences among women younger than 40 
years, survival remained lower for AA women at 81.0% in contrast to 84.3% for AI/AN 
women and 84.8% for white women (Table 3). Among women ages 40-49 and 50-59, both 
AI/ANs and AAs were significantly lower than whites (p<0.0001). Among women ages 
60-69, AI/ANs and AAs were also significantly worse (p=0.005 and p<0.0001, 
respectively). Additionally, among women ages 70 and older, AI/ANs and AAs were also 
significantly worse (p=0.005 and p<0.0001 respectively).
Furthermore, AA women living in both metropolitan (p<0.0001) and non-metropolitan 
(p=0.006) areas had lower observed survival in contrast to white women, whereas AI/AN 
women did not (Table 3). Married AA women (78.1%) had significantly decreased observed 
survival in contrast to white women (85.9%) (p<0.0001), although there were no differences 
among single women (Table 3). AI/AN women had significantly higher survival (86.9%) 
than white women (p=0.03). Among those who were insured at diagnosis, 84.0% of AAs 
survived five years in contrast to 89.7% of white women (p<0.0001). Again, AI/AN women 
had significantly higher survival (90.2%) than white women (p=0.02). AA women with 
Medicare had an observed survival of 65.4% in contrast to white women at 72.5% 
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(p=0.0003) (Table 3). Finally, women who were diagnosed at in situ or localized stage 
showed no significant differences by race (Table 3). However, AA women (67.6%) who 
were diagnosed at regional stage had poorer five-year survival compared to white women 
(74.9%) (p<0.0001). Finally, AA women (12.6%) who were diagnosed at distant stage had 
poorer five-year survival compared to white women (24.4%) and they were lower than 
AI/AN women (30.2%) (p=0.004).
Prostate Cancer
Overall, 77.5% of men diagnosed with prostate cancer survived for five years (all groups 
were significant at a p<0.0001 unless stated otherwise; Table 1). The proportion of AA men 
diagnosed with prostate cancer was 7.4% in contrast to 5.4% of those diagnosed with 
prostate cancer overall. There was a small, but statistically significant improvement in 
overall survival for men diagnosed with prostate cancer from 1997-2000, to 2001-2004 and 
2005-2008 at 75.0%, 77.2%, and 80.0% respectively. Those who reported Hispanic ethnicity 
had a higher five-year survival at 84.3% compared to non-Hispanic ethnicity at 77.4%. 
Those aged 70 years and older were less likely than other age groups to survive for five 
years. Men living in non-metropolitan counties at diagnosis were less likely to survive five 
years at 75.0% compared to those in metropolitan counties at 79.2%. Those who were 
married were significantly more likely to survive five years at 82.5% in contrast to those 
who were single at 74.9% or whose marital status was unknown at 63.6%.
Also, there were significant differences between men who were insured and those with other 
primary payer sources (Table 1). Those with insurance as their primary payer at diagnosis 
had the highest five-year survival at 90.8% in contrast to those with VA/TRICARE/Military 
at 82.0%, those with Medicare at 73.3%, those with Medicare and Medicaid 67.1%, those 
with Medicaid at 59.0%, those who were uninsured at 56.1%, and those with unknown 
primary payer at 71.4%.
Regarding stage, there were no differences in observed survival between in situ at 81.3%, 
localized at 83.1%, and regional at 84.2%. However, those diagnosed at distant stage had 
lower survival (22.5%) compared to those diagnosed with in situ tumors (Table 1). Those 
with unstaged cases had 51.7% five-year survival.
White and AI/AN men had similar five-year observed survival at 77.5% and 77.7% 
respectively in contrast to 75.2% among AA men (p=0.0002) (Table 1). Among older age 
groups, AA men had increased disparities compared to whites: aged 50-59 years at 88.9% 
compared to 92.6% for whites (p<0.0001); aged 60-69 years at 81.6% compared to 87.4% 
for whites (p<0.0001); aged 70 years and older at 52.5% compared to 65.6% for whites 
(p<0.0001). AA men living in both metropolitan areas (76.6%) (p=0.002) and non-
metropolitan areas (70.2%) (p=0.06) had slightly lower observed survival compared to white 
men (79.4%) and (75.0%) respectively (Table 4). Among AAs who had Medicare as their 
primary payer at diagnosis, 68.8% survived five years compared to 73.4% among white men 
(p=0.003). AI/AN men (79.6%) whose diagnosis was reported at regional stage had worse 
five-year survival compared to white men (84.1%) (p=0.005). AI/AN men (64.9%) whose 
diagnosis was reported at an unknown stage had marginally better five-year survival 
compared to white men (50.7%) (p=0.07).
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Lung and Bronchus Cancer
Overall, 12.9% of those diagnosed with lung and bronchus cancer survived for five years (all 
groups were significant at a p<0.0001 unless stated otherwise; Table 1). There was a small, 
but statistically significant improvement in overall survival for individuals diagnosed with 
lung and bronchus cancer from 1997-2000, to 2001-2004 and 2005-2008 at 11.4%, 12.9%, 
and 14.4 % respectively (Table 1). Those younger than 40 years were 3.7 times more likely 
to survive five years (33.9%) in contrast to those aged 70 years or older (9.2%). Those living 
in non-metropolitan counties at diagnosis were slightly less likely to survive five years with 
12.3% in compared to metropolitan counties at 13.4%. Those who were married were 
significantly more likely to survive five years at 14.7% in contrast to those that were single 
at 12.6% or whose marital status was unknown at 10.0%. There was a statistically significant 
difference between those insured and those with other primary payer sources. However, 
9.4% of those who were uninsured, 10.8% for those with Medicaid, 11.6% for those with 
Medicare, 9.6% for those with both Medicare and Medical, 12.5% for those with VA/
TRICARE/Military and 11.2% for those with unknown primary payer were all less likely to 
survive five years in contrast to those with primary payer at insurance (19.3%).
As expected, as stage of diagnosis became later, the percentage surviving lung and bronchus 
cancer at five years declined: 29.6% of those diagnosed at in situ; 34.0% of those diagnosed 
at localized; 16.2% of those diagnosed at regional; and 3.5% of those diagnosed at distant 
stage (Table 1). Those unstaged at diagnosis had 8.0% five-year survival.
Among those diagnosed with lung and bronchus cancer, fewer disparities by race were 
observed compared to other cancer sites. AI/ANs diagnosed with lung cancer in 1997-2000 
(13.9%) had a marginally higher observed survival in contrast to whites (11.4%) (p=0.08). 
AI/ANs diagnosed with lung cancer in 2005-2008 (11.5%) had lower observed survival in 
contrast to whites (14.5%) (p=0.01), but there was no difference by race in 2001-2004. 
Among those aged 60-69 years, AAs (9.8%) diagnosed with lung cancer were less likely to 
survive five years compared to whites (15.6%) (p=0.01). Married AAs diagnosed with lung 
and bronchus cancer (11.5%) showed a slight but marginally significant decreased observed 
survival compared to whites (14.7%) (p=0.06) but no difference among those reported as 
single. There was no significant difference based on race for sex, rural/urban continuum, 
primary payer, or stage at diagnosis (Table 5).
Colon and Rectum Cancer
Overall, 49.9% of those diagnosed with colorectal cancer survived for five years (all groups 
were significant at a p<0.0001 unless stated otherwise; Table 1). There was a small, but 
significant improvement in overall survival for individuals diagnosed with colorectal cancer 
from 1997-2000, to 2001-2004 and 2005-2008 at 46.5%, 50.6%, and 52.8%, respectively. 
Those aged 70 years and older were less likely to survive five years at 41.6% in contrast to 
those in all other age groups. Furthermore, there was a small, but significant difference in 
observed survival between men at 48.8% and women at 51.0% (p=0.003). Those living in 
non-metropolitan counties were slightly less likely to survive five years with 48.2% 
compared to those in metropolitan counties at 51.2%. Additionally, those who were married 
were significantly more likely to survive five years at 56.3% in contrast to those that were 
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single at 47.7% or whose marital status was unknown at 40.2%. Those with insurance as 
their primary payer at diagnosis had the highest survival at 63.8%. Those with the following 
primary payer sources were less likely to survive five years than those with insurance: 
Medicare and Medicaid at 36.3%, those uninsured at 40.1%, those with Medicaid at 40.1%, 
those with Medicare at 46.3%, those with IHS at 49.2%, those with VA/TRICARE/Military 
at 51.1%, and those with unknown primary payer at 44.9%. As expected, as stage of 
diagnosis increased, the percentage surviving colorectal cancer at five years worsened: 
78.0% of those diagnosed at in situ; 69.2% of those diagnosed at localized; 53.3% of those 
diagnosed at regional; and 11.3% of those diagnosed at distant stage. Those unstaged at 
diagnosis had 26.5% five-year survival.
Survival from colorectal cancer indicated disparities between AAs (43.1%) and whites 
(50.5%), with AI/ANs in between at 47.6% (p=0.0001) (Table 1). While the percent 
surviving five years increased during the periods 2001-2004 for whites and AAs, there was 
no substantial change for AI/ANs (Table 6). Among AAs diagnosed with colorectal cancer 
in 1997-2000 35.3% survived five years compared to whites at 47.2% (p=0.006). 
Additionally, among AAs in 2005-2008, 46.4% survived five years compared to whites at 
53.7% (p=0.006). Among AI/AN in 2005-2008, 47.6% survived five years compared to 
whites at 53.7% (p=0.01). All age groups had significant differences between AA and whites 
except the youngest age groups (aged 40-49 p=0.0006, aged 50-59 p=0.003, aged 60-69 
p=0.004 and aged 70 years and older p<0.0001). Additionally, survival for all age groups 
significantly differed between AI/ANs and whites except the youngest age groups (40-49 
p=0.0004, 50-59 p=0.007, 60-69 p=0.008 and 70 and older p=0.003). AA and AI/AN men 
had lower observed survival at 40.5% (p=0.0002) and 44.4% (p=0.008), respectively, 
compared to whites at 49.6%. AAs living in both metropolitan areas (43.9%) (p=0.008) and 
non-metropolitan areas (40.3%) (p=0.0007) had lower observed survival in contrast to 
whites at 51.8% in metropolitan and 48.8% in non-metropolitan counties. AI/ANs living in 
both non-metropolitan areas at 44.3% had lower observed survival compared to whites at 
48.8% (p=0.03) (Table 6). Married AAs (48.7%) had significantly decreased observed 
survival compared to whites (56.7%) (p=0.02). Furthermore, AAs and AI/ANs who had 
Medicare at diagnosis had a five-year survival rate of 35.9% and 42.5% compared 47.0% 
among whites (p<0.0001 and p=0.0002 respectively). There was no significant difference 
among racial groups based on stage at diagnoses (Table 6).
DISCUSSION
In this study, the five-year observed survival rates in Oklahoma were consistent with national 
trends.37 Overall, cancer survival seems to be improving over time, but there remains serious 
disparity with AA population compared to whites in Oklahoma. To a lesser extent, there 
were also disparities in survival between AI/ANs and whites in Oklahoma, which is 
consistent with previous studies indicating AI/ANs have poorer survival in other parts of the 
US.24,25,37
In some cases, the percentage surviving five years for a specific demographic group were as 
much as 2.4 times worse for AAs compared to whites, but this trend was not consistent. The 
few instances where AA survival was higher than whites or AI/ANs were notable for their 
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rarity. While this is consistent with national trends, it is still important to note and to 
highlight the work that still needs to be done to reduce these long standing and critical 
disparities in the US and in Oklahoma.37 Future analytical studies should identify and 
control for confounding and determine whether effect modification is present in order to 
better understand racial disparities in Oklahoma.6,8,11,13,29,38
Overall, older aged patients had lower survival. This was to be expected given that only 
observed survival or all-cause survival was used. Those with primary payer as Medicare also 
indicated lower overall observed survival. As reported nationally, males tend to have 
decreased survival compared to females.37 Individuals who lived in non-metropolitan 
counties also tended to have lower survival compared to those living in metropolitan areas at 
diagnosis. Further research is recommended using smaller spatial areas (such as census 
tracts), as county-based categories may be too geographically heterogeneous to show true 
disparities.
This study also suggested an important disparity by marital status at diagnosis. For the most 
part, those married at diagnosis were more likely to survive five years. This was true for all 
racial groups and for each specific cancer and suggests the importance of support for cancer 
patients. However, further analytic research is recommended controlling for confounding 
factors such as age, race, SES to determine if this remains important.
Primary payer at diagnosis is a complicated factor that has been shown to be important for 
cancer surivival.39 Generally when the primary payer at diagnosis was private insurance, 
survival was better. In a few strata VA/TRICARE/Military also indicated improved survival. 
Often those on Medicaid and those who were uninsured had poorer survival. Again, further 
research controlling for confounding factors such as age, race, and SES is extremely 
important as these factors impact insurance coverage. It will also be interesting to follow 
trends in insurance coverage over time with the implementation of the Affordable Care Act 
in 2010, which has reduced the numbers of the uninsured population from 20.3% in 2012 to 
13.2% in 2015.40
One note that deserves further attention is the lack of dramatic disparity in observed survival 
among the racial groups for lung cancer. While previous studies indicated significant lung 
and bronchus cancer disparities by race, the disparities observed – particularly in the early 
years of 1997-2001, those aged 60-69 years and those who were married – were not nearly 
as dramatic as in other cancers.41,42 A more intense review of racial disparities in lung and 
bronchus cancer is recommended with the hope to begin observing an end to disparities in 
survival of this very fatal cancer, which was also observed in a study of US Veteran 
population.43
As mentioned above, there appear to be disparities in survival between AI/ANs and whites 
in Oklahoma consistent with previous studies.24,25,37 However, this disparity is evident 
primarily in overall cancer survival and in colorectal cancer but not consistently in other 
specific cancers. Therefore, analysis of additional cancers is needed to determine whether 
the overall differences between AI/ANs and whites were due to rarer cancers that cannot as 
easily be treated by IHS or Tribal Health Facilities. Finally, the primary payer among 
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AI/ANs is often complicated by the confusion of health facility staff as well as those 
providing insurance, because many AI/AN with IHS or Tribal Health coverage are rarely 
asked to provide this information if seeking medical help at an IHS or Tribal Health Facility. 
This is evidenced throughout this study as AI/ANs typically have the highest percentage of 
unknown primary payer.
An important topic to keep in mind for future studies is the issue of increasing individual 
who report they are multiple races. Oklahoma is unique in the 5.9% who report they are two 
or more races in the census.4 In fact, not a great deal of work has been done with people who 
report multiple races and how this affects their health outcomes. The complex issues of race, 
racism, access to care, cultural differences and genetic distribution none of which we 
understand in detail. Further exploration of the differences in survival for specific 
geographic areas is recommended as there are dramatic differences between and among 
tribal nations regarding risk factors, treatment, and access to care. Action should be taken at 
tribal, local, state as well as federal level, as cancer is a major problem among AI/AN 
population in Oklahoma and the US.5,25,44-48 A final issue that needs to be addressed is that 
these data reflect statewide population-based information. They do not represent tribal health 
services or the IHS user population thus does not reflect on the quality of care provided by 
tribal health services, tribal programs or IHS. It is important to note that in some cancers that 
have been a focus of tribal health services, female breast cancer in this study, shows no 
significant difference between AI/AN and whites. We have seen this is other studies and it 
does suggest that focused screening and treatment programs may be beginning to show 
successes.49,50
STRENGTHS AND LIMITATIONS
There were several strengths to this study: the large database, the high quality data, the death 
linkages, and the presumed alive methodology. The OCCR data set is the only large data set 
of cancer patients for Oklahoma and it allowed us to make reasonable cancer survival 
estimates that can be generally applicable to the population in Oklahoma.28
Nonetheless, there were several limitations encountered while performing this study. First, 
the most important limitation in the study was that OCCR does not conduct active follow-up 
of the patients or NDI linkage every year and therefore, survival may still be overestimated. 
However, according to a recent review of central cancer registry data, the presumed alive 
methodology results in minimal underestimation.28,29 This underestimation would most 
likely occur among Hispanic and Asian populations primarily due to the higher proportion 
of emigrants in these populations and due to small sample size were not reviewed in detail 
for this study.29 Of concern is that NDI linkage is not completed each year at OCCR. The 
large majority of cases will be updated with Oklahoma Mortality Data and the Social 
Security Death Index to identify those who are deceased. There may be an artificial inflation 
of the rates for recent years. We will continue to review these in future years.
A second limitation of this study was the use of crude observed survival, rather than one of 
the other methods such as relative survival, cause-specific survival, age-adjusted survival, or 
median survival.37,51 For cancers with dismal survival rates such as lung cancer, five-year 
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observed survival may not be the optimal survival measure. The decision of which survival 
methods to use in a cancer study is complex.28,29,51-53 Observed survival is the proportion of 
people with a particular cancer who are alive at a certain point in time after their diagnosis, 
thus includes deaths from causes other than the specific cancer. Therefore, a confounding 
factor may be co-morbidity and competing causes of death, such as in diabetes among 
AI/AN and AA populations. This can be particularly true when looking at groups that have 
disparities in death from many causes. For this study, observed survival was the best choice 
as the study was descriptive.53
A third limitation of this study was not accounting for incidence, mortality or screening. 
Improved survival is only a strength when it is accompanied by decreased burden of 
disease.1 Apparent improved survival can occur when disease burden is increased due to 
certain biases including lead time (the systematic error of apparent increased survival from 
detecting disease in an early stage), length (the systematic error from detecting disease with 
a long latency or pre-clinical period), referral (the systematic error from detecting disease in 
persons who have a tendency to seek health care) and detection (the detection of 
insignificant disease) being introduced, and without incidence, mortality and screening data, 
true survival differences cannot be known.
A fourth limitation of this study was potential confounding and effect modification. As this 
study was descriptive in nature, these potential effects were not evaluated. Differences by the 
demographic variables often contribute to confounding as well as behavioral factors not 
typically collected by cancer registries. A multivariate or stratified analysis is recommended 
to further explore and account for these factors.
Fifth, biases are often associated with cancer registry data collection including “immortal” 
cancer patients who have a diagnosis but are immediately lost to follow-up due to moving 
outside of the US where the NDI or other methods would not identify their death. This may 
explain the higher percentage of survival among Hispanics in our study. To control for this, 
those who had zero days or less than zero days of survival in our study were eliminated.
Finally, the percent of missing data was concerning for some variables, namely marital status 
with 28% unknown, primary payer at diagnosis with 8.8% missing and stage at diagnosis 
with 12.3% missing or unknown. Missing data were analyzed as a unique category for each 
of the variables. As discussed above, cases with zero days or less than zero days of survival 
were deleted in our study with 1.7% of the total study.
CONCLUSION
In conclusion, this study provides information on observed survival rates for all cancers 
combined and for specific cancer sites in Oklahoma. This is the first known population-
based race-specific study on cancer survival rates in Oklahoma. The cancer survival rates 
were poorer among the AA population and, to a lesser extent, among the AI/AN population 
in Oklahoma. Additional research is encouraged to clarify survival in Oklahoma including 
relative survival, cause-specific survival and multivariable analysis. There are numerous 
opportunities to address disparities in cancer, such as patient navigation, physician 
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education, and health literacy, and this should be the focus of future analyses and 
interventional studies.54 Addressing such issues would influence better understanding of the 
burden and survival of cancer among Oklahomans.
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Table 2
Five-year observed survival, 95% confdence intervals and log-rank p-values for all cancers by selected 












 1997-2000 50.8 (49.3, 52.3) 48.3 (47.9, 48.8) 42.2 (40.6, 43.9) <0.0001
 2001-2004 52.0 (50.6, 53.3) 51.7 (51.3, 52.1) 47.7 (46.1, 49.3) 0.0002
 2005-2008 50.1 (48.8, 51.4) 54.5 (54.1, 54.9) 50.5 (49.0, 52.1) <0.0001
Age Group (years)
 <40 74.2 (71.7, 76.5) 78.6 (77.7, 79.5) 68.3 (64.9, 71.5) <0.0001
 40-49 63.8 (61.5, 66.0) 70.0 (69.2, 70.7) 61.6 (58.9, 64.2) <0.0001
 50-59 56.7 (54.9, 58.4) 63.4 (62.9, 64.0) 55.2 (53.2, 57.2) <0.0001
 60-69 52.1 (50.6, 53.7) 56.4 (56.0, 56.9) 49.0 (47.2, 50.8) <0.0001
 ≥70 36.4 (35.1, 37.8) 38.6 (38.3, 39.0) 32.0 (30.5, 33.4) <0.0001
Sex
 Male 45.9 (44.7, 47.0) 47.9 (47.5, 48.2) 45.2 (44.0, 46.5) <0.0001
 Female 55.4 (54.4, 56.5) 55.5 (55.2, 55.9) 49.1 (47.8, 50.4) <0.0001
Rural/Urban
Continuum
 Metropolitan 53.2 (52.0, 54.4) 53.5 (53.2, 53.8) 48.7 (47.7, 49.8) <0.0001
 Non-
 Metropolitan
49.0 (47.9, 50.1) 48.9 (48.6, 49.3) 41.1 (39.2, 43.1) <0.0001
Marital Status
 Married 55.9 (54.7, 57.1) 56.8 (56.5, 57.1) 53.4 (51.9, 54.9) <0.0001
 Single 48.4 (46.8, 50.1) 50.0 (49.4, 50.6) 47.6 (46.0, 49.3) 0.04
 Unknown 45.3 (43.9, 46.7) 42.4 (41.9, 42.8) 37.9 (36.2, 39.6) <0.0001
Primary Payer
 Uninsured 34.5 (31.3, 37.8) 40.3 (39.4, 41.2) 37.6 (34.5, 40.7) 0.01
 Insured 68.0 (66.4, 69.5) 68.9 (68.5, 69.3) 63.7 (62.1, 65.3) <0.0001
 Medicaid 46.1 (43.1, 49.0) 43.3 (42.1, 44.4) 42.8 (39.8, 45.7) 0.05
 Medicare 42.5 (41.2, 43.8) 44.4 (44.0, 44.7) 39.0 (37.5, 40.5) <0.0001
 Medicare/
 Medicaid
31.6 (26.9, 36.4) 33.3 (31.4, 35.2) 32.8 (28.4, 37.3) 0.12
 VA/Tricare
 Military
48.9 (43.2, 54.3) 48.4 (47.1, 49.8) 50.6 (46.8, 54.2) 0.28
 Indian Health
 Services
55.5 (53.2, 57.8) 55.9 (45.7, 64.9) 0.42
 Unknown 55.1 (52.6, 57.6) 48.0 (47.2, 48.8) 39.1 (35.6, 42.5) <0.0001
Stage
 In Situ 84.9 (82.0, 87.3) 84.6 (83.9, 85.3) 86.7 (83.3, 89.5) 0.62
























 Localized 71.9 (70.7, 73.1) 71.9 (71.6, 72.2) 72.0 (70.6, 73.3) 0.86
 Regional 49.2 (47.5, 50.9) 49.0 (48.4, 49.5) 46.0 (43.9, 48.0) 0.11
 Distant 20.9 (19.5, 22.2) 18.3 (17.9, 18.6) 15.2 (13.9, 16.5) <0.0001
 Unstaged 33.8 (31.7, 35.9) 31.4 (30.7, 32.0) 26.9 (24.6, 29.2) 0.0004
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Table 3
Five-year observed survival, 95% confdence intervals and log-rank p-values for female breast cancer by 












 1997-2000 77.4 (74.2, 80.4) 76.7 (75.8, 77.5) 68.6 (64.5, 72.3) <0.0001
 2001-2004 82.0 (79.2, 84.5) 80.0 (79.3, 80.8) 73.8 (70.3, 77.0) 0.01
 2005-2008 80.6 (77.9, 83.0) 81.5 (80.7, 82.3) 76.7 (73.4, 79.6) 0.0001
Age Group
(years)
 <40 84.3 (77.9, 89.1) 84.8 (82.5, 86.8) 81.0 (73.9, 86.4) 0.21
 40-49 82.8 (79.0, 86.0) 88.3 (87.3, 89.3) 84.0 (80.0, 87.2) <0.0001
 50-59 87.2 (84.3, 89.5) 87.1 (86.3, 87.9) 76.9 (72.8, 80.4) <0.0001
 60-69 83.9 (80.6, 86.6) 83.9 (83.1, 84.7) 75.4 (70.8, 79.4) <0.0001
 ≥70 65.8 (61.8, 69.5) 67.2 (66.3, 68.1) 57.3 (52.8, 61.5) <0.0001
Rural/Urban
Continuum
 Metropolitan 82.2 (79.9, 84.3) 80.7 (80.1, 81.2) 74.5 (72.2, 76.5) <0.0001
 Non-
 Metropolitan
78.3 (75.9, 80.4) 77.3 (76.6, 78.1) 68.6 (63.5, 73.1) <0.0001
Marital Status
 Married 86.9 (84.8, 88.7) 85.9 (85.4, 86.5) 78.1 (74.8, 81.0) <0.0001
 Single 77.6 (73.7, 81.0) 77.7 (76.4, 78.9) 76.6 (73.3, 79.6) 0.66
 Unknown 71.5 (68.2, 74.6) 67.7 (66.7, 68.7) 63.5 (59.4, 67.3) 0.0003
Primary Payer
 Uninsured 68.3 (58.4, 76.3) 68.5 (66.2, 70.6) 61.3 (53.0, 68.6) 0.14
 Insured 90.2 (87.9, 92.0) 89.7 (89.1, 90.2) 84.0 (81.3, 86.3) <0.0001
 Medicaid 75.4 (68.9, 80.7) 70.2 (67.6, 72.7) 65.7 (58.7, 71.8) 0.12
 Medicare 72.4 (68.9, 75.5) 72.5 (71.7, 73.3) 65.4 (61.2, 69.3) 0.0005
 Medicare/
 Medicaid
75.0 (56.2, 86.6) 53.8 (48.1, 59.1) 67.1 (54.8, 76.8) 0.14
 VA/Tricare
 Military
88.2 (60.6, 96.9) 91.9 (88.8, 94.2) 86.4 (72.1, 93.6) 0.37
 Indian Health
 Services
83.0 (78.5, 86.6) 77.4 (58.4, 88.5) suppressed 0.92
 Unknown 74.6 (68.5, 79.6) 73.8 (71.8, 75.6) 61.2 (50.8, 70.1) 0.0003
Stage
 In Situ 92.9 (89.7, 95.2) 92.8 (92.1, 93.6) 93.9 (90.5, 96.1) 0.77
 Localized 87.9 (85.8, 89.7) 85.8 (85.2, 86.3) 85.9 (83.2, 88.1) 0.22
 Regional 74.0 (70.6, 77.1) 74.9 (73.9, 75.9) 67.6 (63.7, 71.2) <0.0001
























 Distant 30.2 (22.4, 38.3) 24.4 (22.3, 26.7) 12.6 (7.9, 18.4) <0.0001
 Unstaged 64.9 (56.7, 71.9) 53.3 (50.9, 55.6) 46.1 (36.8, 54.9) 0.0006
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Table 4
Five-year observed survival, 95% confdence intervals and log-rank p-values for prostate cancer by selected 












 1997-2000 76.3 (72.2, 79.8) 75.2 (74.2, 76.1) 70.4 (66.7, 73.8) 0.0004
 2001-2004 76.8 (73.3, 79.9) 77.3 (76.4, 78.2) 75.0 (71.6, 78.1) 0.16
 2005-2008 79.8 (76.4, 82.8) 79.9 (79.0, 80.8) 79.5 (76.4, 82.2) 0.58
Age Group
(years)
 <40 suppressed 81.8 (44.7, 95.1) 100.0 0.40
 40-49 86.7 (68.3, 94.8) 93.4 (90.7, 95.4) 96.8 (90.4, 99.0) 0.29
 50-59 88.2 (84.1, 91.4) 92.6 (91.7, 93.4) 88.9 (85.7, 91.5) <0.0001
 60-69 87.1 (84.3, 89.4) 87.4 (86.7, 88.1) 81.6 (78.6, 84.2) <0.0001
 ≥70 64.8 (61.2, 68.1) 65.6 (64.7, 66.5) 58.5 (55.0, 61.9) <0.0001
Rural/Urban
Continuum
 Metropolitan 80.1 (77.0, 82.8) 79.4 (78.7, 80.0) 76.6 (74.4, 78.6) 0.003
 Non-
 Metropolitan
76.0 (73.2, 78.5) 75.0 (74.1, 75.8) 70.2 (65.7, 74.3) 0.07
Marital Status
 Married 83.2 (80.7, 85.4) 82.5 (81.9, 83.0) 82.4 (80.1, 84.5) 0.49
 Single 78.3 (72.8, 82.9) 74.5 (72.6, 76.3) 74.5 (70.2, 78.4) 0.73
 Unknown 65.9 (61.4, 70.0) 63.4 (62.1, 64.7) 58.1 (53.6, 62.4) 0.004
Primary Payer
 Uninsured 63.2 (49.3, 74.2) 55.3 (51.9, 58.6) 54.3 (43.7, 63.7) 0.25
 Insured 89.6 (86.0, 92.2) 90.9 (90.1, 91.5) 90.6 (88.0, 92.6) 0.02
 Medicaid 52.0 (37.4, 64.7) 58.4 (52.5, 63.8) 64.1 (53.4, 73.0) 0.50
 Medicare 73.4 (70.3, 76.2) 73.4 (72.7, 74.2) 68.8 (65.4, 71.8) 0.007
 Medicare/
 Medicaid
78.6 (58.4, 89.8) 62.5 (54.3, 69.7) 71.8 (54.9, 83.3) 0.97
 VA/Tricare
 Military
86.0 (72.9, 93.1) 81.6 (78.7, 84.1) 82.4 (76.7, 86.8) 0.83
 Indian Health
 Services
86.8 (80.2, 91.2) 66.7 (44.3, 81.7) 85.7 (33.4, 97.9) 0.08
 Unknown 74.3 (66.9, 80.2) 71.9 (69.9, 73.8) 58.4 (50.7, 65.3) <0.0001
Stage
 In Situ suppressed 81.3 (52.5, 93.5) suppressed NA
 Localized 82.5 (80.4, 84.5) 83.1 (82.5, 83.6) 83.5 (81.5, 85.2) 0.05
 Regional 79.6 (72.4, 85.1) 84.1 (82.5, 85.6) 88.8 (82.9, 92.7) 0.003
























 Distant 21.5 (13.3, 31.1) 23.0 (20.4, 25.7) 19.1 (13.1, 26.0) 0.46
 Unstaged 66.3 (59.0, 72.6) 50.7 (48.7, 52.7) 40.9 (34.2, 47.5) <0.0001
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Table 5
Five-year observed survival, 95% confdence intervals and log-rank p-values for lung and bronchus cancer by 












 1997-2000 13.9 (11.3, 16.7) 11.4 (10.8, 12.0) 8.0 (5.9, 10.5) 0.004
 2001-2004 13.4 (11.1, 15.9) 12.9 (12.3, 13.6) 11.3 (9.0, 13.9) 0.58
 2005-2008 11.5 (9.6, 13.5) 14.5 (13.9, 15.2) 14.3 (11.7, 17.2) 0.02
Age Group
(years)
 <40 50.0 (30.6, 66.6) 31.3 (24.7, 38.1) 25.9 (11.5, 43.1) 0.07
 40-49 15.3 (10.4, 21.1) 19.8 (17.7, 22.0) 13.3 (8.3, 19.6) 0.15
 50-59 16.5 (13.3, 20.1) 17.1 (16.0, 18.2) 18.2 (14.6, 22.2) 0.99
 60-69 14.8 (12.4, 17.4) 15.6 (14.9, 16.4) 9.8 (7.4, 12.6) 0.02
 ≥70 7.9 (6.3, 9.6) 9.3 (8.9, 9.8) 7.8 (5.9, 9.9) 0.09
Sex
 Male 10.5 (8.9, 12.2) 11.0 (10.6, 11.5) 9.4 (7.7, 11.2) 0.60
 Female 15.4 (13.4, 17.6) 15.6 (15.0, 16.2) 14.3 (11.8, 17.0) 0.88
Rural/Urban
Continuum
 Metropolitan 13.1 (11.1, 15.2) 13.5 (12.9, 14.0) 11.9 (10.2, 13.7) 0.57
 Non-
 Metropolitan
12.5 (10.8, 14.3) 12.3 (11.8, 12.9) 9.6 (7.0, 12.7) 0.14
Marital Status
 Married 14.0 (12.0, 16.1) 14.7 (14.2, 15.3) 11.5 (9.3, 14.1) 0.04
 Single 12.8 (10.2, 15.6) 12.4 (11.6, 13.4) 12.9 (10.4, 15.8) 0.38
 Unknown 10.7 (8.5, 13.1) 9.9 (9.3, 10.6) 9.2 (6.9, 12.0) 0.34
Primary Payer
 Uninsured 6.7 (3.4, 11.4) 9.1 (7.9, 10.3) 12.8 (8.5, 18.0) 0.05
 Insured 21.3 (17.4, 25.5) 19.3 (18.3, 20.3) 16.9 (13.3, 20.8) 0.21
 Medicaid 11.5 (7.1, 17) 10.3 (8.7, 12.0) 13.4 (9.0, 18.7) 0.24
 Medicare 10.7 (9.0, 12.6) 11.7 (11.2, 12.2) 9.2 (7.2, 11.5) 0.17
 Medicare/
 Medicaid
6.7 (2.5, 13.8) 10.2 (7.9, 12.9) 4.5 (1.2, 11.4) 0.10
 VA/Tricare
 Military
12.3 (5.8, 21.5) 12.6 (10.9, 14.5) 10.5 (6.2, 16.1) 0.89
 Indian Health
 Services
14.3 (10.5, 18.8) 28.6 (8.8, 52.4) suppressed 0.88
 Unknown 13.3 (9.1, 18.4) 11.3 (10.1, 12.5) 4.5 (1.5, 10.2) 0.11
Stage
























 In Situ suppressed 31.8 (14.2, 51.1) 50.0 (0.6, 91.0) 0.17
 Localized 34.6 (30.3, 38.9) 34.0 (32.8, 35.2) 31.5 (26.1, 37.1) 0.56
 Regional 15.4 (12.6, 18.5) 16.1 (15.3, 17.0) 16.3 (13.0, 20.1) 0.37
 Distant 3.3 (2.3, 4.5) 3.5 (3.2, 3.8) 3.9 (2.8, 5.3) 0.35
 Unstaged 8.2 (5.6, 11.5) 7.9 (7.1, 8.8) 5.8 (3.1, 9.5) 0.94
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Table 6
Five-year observed survival, 95% confdence intervals and log-rank p-values for colorectal cancer by selected 












 1997-2000 46.8 (41.7, 51.6) 47.2 (45.9, 48.5) 35.3 (30.5, 40.1) 0.0006
 2001-2004 48.2 (43.7, 52.6) 50.9 (49.5, 52.2) 47.6 (42.5, 52.6) 0.16
 2005-2008 47.6 (43.2, 51.8) 53.7 (52.3, 55.1) 46.4 (41.3, 51.4) 0.01
Age Group
(years)
 <40 57.9 (44.1, 69.5) 66.0 (60.2, 71.1) 57.5 (40.8, 71.0) 0.75
 40-49 56.0 (46.5, 64.5) 64.2 (60.8, 67.3) 51.8 (42.1, 60.7) 0.001
 50-59 55.6 (49.0, 61.7) 63.1 (61.0, 65.1) 53.2 (46.4, 59.6) 0.005
 60-69 52.7 (47.4, 57.7) 59.1 (57.5, 60.7) 50.9 (44.8, 56.7) 0.006
 ≥70 39.1 (35.3, 43.0) 42.3 (41.3, 43.3) 31.4 (27.4, 35.5) <0.0001
Sex
 Male 44.4 (40.6, 48.1) 49.6 (48.5, 50.7) 40.5 (36.4, 44.5) 0.0004
 Female 50.6 (46.8, 54.2) 51.3 (50.2, 52.4) 45.7 (41.5, 49.7) 0.08
Rural/Urban
Continuum
 Metropolitan 52.0 (47.9, 56.0) 51.8 (50.7, 52.8) 43.9 (40.6, 47.2) 0.002
 Non-
 Metropolitan
44.3 (40.8, 47.7) 48.8 (47.6, 50.0) 40.3 (34.3, 46.2) 0.001
Marital Status
 Married 53.8 (49.8, 57.7) 56.7 (55.7, 57.8) 48.7 (44.0, 53.2) 0.02
 Single 45.5 (39.8, 51.0) 48.3 (46.2, 50.4) 45.1 (39.7, 50.3) 0.72
 Unknown 40.8 (36.4, 45.2) 40.4 (39.1, 41.8) 33.8 (28.9, 38.8) 0.01
Primary Payer
 Uninsured 35.3 (25.3, 45.4) 41.1 (38.0, 44.3) 33.3 (24.1, 42.8) 0.91
 Insured 66.0 (60.0, 71.4) 64.0 (62.5, 65.4) 59.6 (54.1, 64.6) 0.17
 Medicaid 44.0 (33.3, 54.3) 39.6 (34.6, 44.6) 35.8 (24.6, 47.2) 0.39
 Medicare 42.5 (38.6, 46.3) 47.0 (46.0, 48.0) 35.9 (31.6, 40.1) <0.0001
 Medicare/
 Medicaid
31.6 (17.7, 46.4) 36.3 (30.6, 42.1) 35.7 (21.7, 49.9) 0.34
 VA/Tricare
 Military
34.6 (17.5, 52.5) 52.6 (47.5, 57.5) 45.3 (31.6, 58.0) 0.19
 Indian Health
 Services
50.0 (40.5, 58.8) 25.0 (0.9, 66.5) suppressed 0.40
 Unknown 50.4 (41.6, 58.5) 44.6 (41.7, 47.5) 37.1 (25.3, 48.9) 0.04
Stage
























 In Situ 65.3 (50.3, 76.8) 78.9 (75.6, 81.8) 75.6 (60.2, 85.6) 0.43
 Localized 66.6 (62.0, 70.8) 69.4 (68.2, 70.6) 65.7 (60.5, 70.4) 0.66
 Regional 53.2 (48.7, 57.4) 53.5 (52.2, 54.8) 49.5 (44.3, 54.4) 0.59
 Distant 11.3 (7.8, 15.4) 11.5 (10.3, 12.6) 7.5 (4.8, 11.1) 0.11
 Unstaged 27.6 (20.1, 35.7) 26.4 (23.9, 28.9) 22.2 (14.9, 30.4) 0.51
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